Caption Management’s Coherus Oncology CHRS Stock Holding History

Caption Management’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-12,000	Closed	-$167K	–	1536
2021 Q2	$167K	Buy	+12,000	New	+$170K	﹤0.01%	1193
2019 Q3	–	Sell	-50,000	Closed	-$999K	–	732
2019 Q2	$1.1M	Buy	+50,000	New	+$868K	0.06%	351

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Caption Management's CHRS Position: Q3 2021 in Review

Caption Management sold out of Coherus Oncology (CHRS) in Q3 2021, closing a stake of 12,000 shares — an estimated $167K sold.

Caption Management first reported a position in CHRS in Q2 2019 and held it in 2 quarters. The position peaked at $1.1M in Q2 2019. 187 funds tracked by Wall St. Rank hold CHRS as of Q3 2021.

Caption Management reported no remaining Coherus Oncology position as of Q3 2021 after selling out during the quarter.
Caption Management sold 12,000 Coherus Oncology shares in Q3 2021, an estimated $167K.
Caption Management first reported a position in Coherus Oncology in Q2 2019 and held it in 2 quarters.
Caption Management's Coherus Oncology position peaked at $1.1M in Q2 2019.
187 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2021.

Based on Caption Management's 13F filing for Q3 2021, filed 12 Nov 2021.